Tema Cardiovascular and Metabolic ETF (HRTS) Holdings
HRTS holdings summary
as of Oct 25, 2026- Holdings
- 46 positions listed
- Top 10 weight
- 47.0% of net assets
- Effective holdings
- 26 equal-weight equivalent
- Largest holding
- LLY 11.53% Eli Lilly and Company
- Annual turnover
- 0.0% of the portfolio traded
All HRTS holdings
| # | Name | ||||||
|---|---|---|---|---|---|---|---|
| 1 | LLY | Eli Lilly and Company | Healthcare | 11.53% | $6.4M | $1.12T | 42.2 |
| 2 | TMO | Thermo Fisher Scientific Inc. | Healthcare | 5.37% | $3.0M | $255.13B | 37.1 |
| 3 | MRK | Merck & Co., Inc. | Healthcare | 4.84% | $2.7M | $360.08B | 115.8 |
| 4 | RHHBY | Roche Holding Ltd ADR | Healthcare | 4.57% | $2.6M | — | — |
| 5 | UNH | UnitedHealth Group Incorporated | Healthcare | 3.88% | $2.2M | $360.32B | 25.8 |
| 6 | RVMD | Revolution Medicines, Inc. | Healthcare | 3.55% | $2.0M | $38.14B | — |
| 7 | KOD | Kodiak Sciences Inc. | Healthcare | 3.42% | $1.9M | $5.39B | — |
| 8 | BBIO | BridgeBio Pharma, Inc. | Healthcare | 3.41% | $1.9M | $12.98B | — |
| 9 | DHR | Danaher Corporation | Healthcare | 3.30% | $1.8M | $161.01B | 40.8 |
| 10 | JNJ | Johnson & Johnson | Healthcare | 3.11% | $1.7M | $615.87B | 38.8 |
| 11 | 0QIU | Novo Nordisk A/S Class B | Other | 3.08% | $1.7M | — | — |
| 12 | NOVN | Novartis AG | Healthcare | 3.04% | $1.7M | — | — |
| 13 | CYTK | Cytokinetics, Incorporated | Healthcare | 2.98% | $1.7M | $8.61B | — |
| 14 | AZN | AstraZeneca PLC | Healthcare | 2.97% | $1.7M | — | — |
| 15 | VRTX | Vertex Pharmaceuticals Incorporated | Healthcare | 2.92% | $1.6M | $126.66B | 28.9 |
| 16 | GILD | Gilead Sciences, Inc. | Healthcare | 2.88% | $1.6M | $193.67B | — |
| 17 | ABT | Abbott Laboratories | Healthcare | 2.83% | $1.6M | $181.50B | 33.8 |
| 18 | ABBV | AbbVie Inc. | Healthcare | 2.72% | $1.5M | $504.37B | 80.6 |
| 19 | ISRG | Intuitive Surgical, Inc. | Healthcare | 2.42% | $1.4M | $150.74B | 48.9 |
| 20 | MDT | Medtronic plc | Healthcare | 2.24% | $1.3M | $121.20B | 23.3 |
| 21 | MCK | McKesson Corporation | Healthcare | 2.09% | $1.2M | $117.15B | 26.9 |
| 22 | SYK | Stryker Corporation | Healthcare | 1.66% | $927,981.55 | $113.02B | 30.5 |
| 23 | 4578 | Otsuka Holdings Ltd | Healthcare | 1.57% | $875,460.62 | — | — |
| 24 | EW | Edwards Lifesciences Corporation | Healthcare | 1.41% | $790,107.13 | $49.92B | 51.5 |
| 25 | DXCM | DexCom, Inc. | Healthcare | 1.35% | $757,722.02 | $32.47B | 34.1 |
| 26 | FXFXX | First American Funds Inc. - Treasury Obligations Fund | Other | 1.27% | $712,304.56 | — | — |
| 27 | BSX | Boston Scientific Corporation | Healthcare | 1.25% | $701,173.93 | $64.33B | 18.0 |
| 28 | CNC | Centene Corporation | Healthcare | 1.25% | $700,670.54 | $34.16B | — |
| 29 | MDGL | Madrigal Pharmaceuticals, Inc. | Healthcare | 1.24% | $696,084.04 | $10.39B | — |
| 30 | TEVA | Teva Pharmaceutical Industries Ltd | Healthcare | 1.19% | $663,531.14 | — | — |
| 31 | REGN | Regeneron Pharmaceuticals, Inc. | Healthcare | 1.12% | $624,881.55 | $81.41B | 19.6 |
| 32 | ILMN | Illumina, Inc. | Healthcare | 1.08% | $605,025.40 | $39.64B | 49.0 |
| 33 | BMY | Bristol-Myers Squibb Company | Healthcare | 1.06% | $594,286.30 | $122.05B | 13.2 |
| 34 | 4519 | Chugai Pharmaceutical Co. Ltd. | Healthcare | 0.96% | $539,695.86 | — | — |
| 35 | ALNY | Alnylam Pharmaceuticals, Inc. | Healthcare | 0.82% | $459,823.78 | $31.02B | 39.1 |
| 36 | AMGN | Amgen Inc. | Healthcare | 0.82% | $457,139.00 | $233.82B | 26.9 |
| 37 | STOK | Stoke Therapeutics, Inc. | Healthcare | 0.73% | $410,099.49 | $1.56B | — |
| 38 | ARWR | Arrowhead Pharmaceuticals, Inc. | Healthcare | 0.56% | $314,957.75 | $7.90B | — |
| 39 | XENE | Xenon Pharmaceuticals Inc. | Healthcare | 0.52% | $291,018.50 | $3.24B | — |
| 40 | SOON | Sonova H Ag | Healthcare | 0.49% | $274,574.25 | — | — |
| 41 | PODD | Insulet Corporation | Healthcare | 0.47% | $264,450.41 | $9.79B | 26.4 |
| 42 | MBX | MBX Biosciences, Inc. | Healthcare | 0.47% | $261,989.37 | $2.39B | — |
| 43 | SRRK | Scholar Rock Holding Corporation | Healthcare | 0.46% | $257,235.08 | $4.86B | — |
| 44 | VKTX | Viking Therapeutics, Inc. | Healthcare | 0.41% | $229,044.93 | $3.20B | — |
| 45 | INSM | Insmed Incorporated | Healthcare | 0.36% | $199,288.67 | $21.02B | — |
| 46 | ZEAL | Zealand Pharma A/S | Healthcare | 0.32% | $177,139.27 | — | — |
Weights as a percentage of net assets. Value held = weight × net assets ($55.9M). Market cap and P/E from each company's latest fundamentals (U.S.-listed stocks).
HRTS sector breakdown
Sum of the weights of the holdings in each sector.
HRTS top industries
HRTS overlap with other ETFs
| ETF | Fund | Overlap | Shared holdings | Expense ratio |
|---|---|---|---|---|
| JDOC | JPMorgan Healthcare Leaders ETF | 53.1% | 24 of 52 | 0.68% |
| DIA | SPDR Dow Jones Industrial Average ETF | 9.5% | 4 of 30 | 0.16% |
| SPY | SPDR S&P 500 ETF | 7.2% | 23 of 502 | 0.09% |
| VTI | Vanguard Total Stock Market ETF | 6.7% | 35 of 2,941 | 0.03% |
| QQQ | Invesco QQQ ETF | 3.5% | 7 of 101 | 0.17% |
| VXUS | Vanguard Total International Stock ETF | 1.7% | 8 of 8,035 | 0.05% |
Overlap = sum over shared holdings of the smaller of the two weights. 100% means identical portfolios.
About the HRTS portfolio
Tema Cardiovascular and Metabolic ETF holds 46 positions. The ten largest make up 47.0% of the fund, so it behaves like a portfolio of about 26 equally weighted stocks. The biggest positions are Eli Lilly and Company (11.53%), Thermo Fisher Scientific Inc. (5.37%), Merck & Co., Inc. (4.84%), Roche Holding Ltd ADR (4.57%), UnitedHealth Group Incorporated (3.88%).
By sector, Healthcare is 95.6%, Other is 4.3%. Holdings data is from the fund's latest portfolio as reported by EODHD on October 25, 2026; positions change as the fund rebalances.
Related: HRTS chart, HRTS performance, HRTS dividends, HRTS valuation, HRTS overview.
HRTS holdings FAQ
How many holdings does HRTS have?
HRTS holds 46 positions as of October 25, 2026.
What are the top 10 holdings of HRTS?
The ten largest holdings are Eli Lilly and Company (11.53%), Thermo Fisher Scientific Inc. (5.37%), Merck & Co., Inc. (4.84%), Roche Holding Ltd ADR (4.57%), UnitedHealth Group Incorporated (3.88%), Revolution Medicines, Inc. (3.55%), Kodiak Sciences Inc. (3.42%), BridgeBio Pharma, Inc. (3.41%), Danaher Corporation (3.30%), Johnson & Johnson (3.11%). Together they are 47.0% of the fund.
What percentage of HRTS is Eli Lilly and Company?
Eli Lilly and Company is the largest holding at 11.53% of net assets, about $6.4M of the fund's $55.9M.
How concentrated is HRTS?
The top 10 holdings are 47.0% of the fund. By the effective number of holdings (1 divided by the sum of squared weights) HRTS behaves like a portfolio of about 26 equally weighted stocks.